Atlas Trials

Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment

Clinical trial NCT06830694 · RECRUITING

Trial details

NCT number
NCT06830694
Sponsor
Se-Hoon Lee
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Small Cell Carcinoma of Lung
Start date
2025-05-13
Primary completion
2027-03-31
Enrollment
50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.